In primary myxofibrosarcoma samples, we clinically validated the whole-cell and nuclear expression of total PAK1 and its phosphorylated form (p-PAK1T423), which exhibited significant associations with PAK1 gene amplification, increases in mRNA abundance, grades and stages, and adverse outcomes. This evidence concerns the gene PAK1 and myxofibrosarcoma.